Effect of omega-3 fatty acids supplementation on cardio-metabolic and oxidative stress parameters in patients with chronic kidney disease: a systematic review and meta-analysis
- PMID: 33933009
- PMCID: PMC8088683
- DOI: 10.1186/s12882-021-02351-9
Effect of omega-3 fatty acids supplementation on cardio-metabolic and oxidative stress parameters in patients with chronic kidney disease: a systematic review and meta-analysis
Abstract
Background: Omega-3 fatty acids (FAs) have been suggested as a beneficial supplement in chronic kidney disease (CKD) patients, but the results of randomized clinical trials (RCTs) are controversial. We conducted a systematic review and meta-analysis to evaluate all the RCTs about the impact of omega-3 FAs supplementation on cardiometabolic outcomes and oxidative stress parameters in patients with CKD.
Methods: We performed a systematic database search in PubMed/MEDLINE, EMBASE, Scopus, Web of Science, and Cochrane Central, up to May 2020. We included all placebo-controlled randomized trials that assessed the effect of omega-3 FAs supplementation on any cardiometabolic outcomes: blood pressure, total cholesterol (TC), low-density lipoprotein (LDL) and high-density lipoprotein (HDL) or triglycerides (TG) and oxidative stress parameters. Data were pooled using DerSimonian-Laird's random-effects model.
Results: Finally, thirteen articles met the inclusion criteria for this review omega-3 FAs supplementation significantly decrease TC (SMD: -0.26; 95% CI: - 0.51, - 0.02; I2 = 52.7%), TG (SMD: -0.22; 95% CI: - 0.43, - 0.02; I2 = 36.0%) and Malondialdehyde (MDA) levels (SMD: -0.91; 95% CI: - 1.29, - 0.54; I2 = 00.0%) and also significantly increase superoxide dismutase (SOD) (SMD: 0.58; 95% CI: 0.27, 0.90; I2 = 00.0%) and Glutathione peroxidase (GPx) (SMD: 0.50; 95% CI: 0.14, 0.86; I2 = 00.0%) activities. However our results show that omega-3 FAs supplementation have no significant effects on HDL, LDL and blood pressure. Conclusion This systematic review and meta-analysis supports current evidence for the clinical benefit of omega-3 FAs intake to improve cardiometabolic parameters in CKD patients. However, well-designed RCTs still needed to provide a conclusive picture in this field.
Keywords: Blood lipids; CKD; Cardio-metabolic outcomes; Omega-3 FAs; Oxidative stress.
Conflict of interest statement
All authors declare no conflicts of interest.
Figures




Similar articles
-
Omega-3 fatty acids supplementation and oxidative stress parameters: A systematic review and meta-analysis of clinical trials.Pharmacol Res. 2019 Nov;149:104462. doi: 10.1016/j.phrs.2019.104462. Epub 2019 Sep 26. Pharmacol Res. 2019. PMID: 31563611
-
Effect of omega-3 fatty acid plus vitamin E Co-Supplementation on oxidative stress parameters: A systematic review and meta-analysis.Clin Nutr. 2020 Apr;39(4):1019-1025. doi: 10.1016/j.clnu.2019.05.004. Epub 2019 May 10. Clin Nutr. 2020. PMID: 31128941
-
Probiotics, prebiotics, and synbiotics for the improvement of metabolic profiles in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials.Crit Rev Food Sci Nutr. 2021;61(4):577-598. doi: 10.1080/10408398.2020.1740645. Epub 2020 Apr 24. Crit Rev Food Sci Nutr. 2021. PMID: 32329633
-
Effect of Probiotic, Prebiotic, and Synbiotic Supplementation on Cardiometabolic and Oxidative Stress Parameters in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis.Clin Ther. 2021 Mar;43(3):e71-e96. doi: 10.1016/j.clinthera.2020.12.021. Epub 2021 Jan 30. Clin Ther. 2021. PMID: 33526314
-
Omega-3 fatty acid supplementation on lipid profiles in dialysis patients: meta-analysis.Arch Med Res. 2014 Aug;45(6):469-77. doi: 10.1016/j.arcmed.2014.06.008. Epub 2014 Jul 8. Arch Med Res. 2014. PMID: 25010561
Cited by
-
The association of in-utero exposure to air pollution and atherogenic index of plasma in newborns.Environ Health. 2024 Feb 19;23(1):22. doi: 10.1186/s12940-024-01059-1. Environ Health. 2024. PMID: 38369478 Free PMC article.
-
Dietary Omega-3 PUFA Intake in Patients with Chronic Kidney Disease: The Association with Vitamin D Deficiency, Intima-Media Thickness and Blood Pressure.J Clin Med. 2024 Sep 20;13(18):5593. doi: 10.3390/jcm13185593. J Clin Med. 2024. PMID: 39337080 Free PMC article.
-
Efficacy and Safety of a High-Energy, Low-Protein Formula Replacement Meal for Pre-Dialysis Chronic Kidney Disease Patients: A Randomized Controlled Trial.Nutrients. 2023 Oct 24;15(21):4506. doi: 10.3390/nu15214506. Nutrients. 2023. PMID: 37960159 Free PMC article. Clinical Trial.
-
Treatment with omega-3 PUFAs does not increase the risk of CYP2E1-dependent oxidative stress and diabetic liver pathology.Front Endocrinol (Lausanne). 2022 Sep 26;13:1004564. doi: 10.3389/fendo.2022.1004564. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36225205 Free PMC article.
-
Omega-3 Fatty Acids Improve Chronic Kidney Disease-Associated Pruritus and Inflammation.Medicina (Kaunas). 2022 Jun 13;58(6):796. doi: 10.3390/medicina58060796. Medicina (Kaunas). 2022. PMID: 35744059 Free PMC article.
References
-
- Khandouzi N, Shidfar F, Agah S, Hosseini AF, Dehnad A. Comparison of the effects of eicosapentaenoic acid and docosahexaenoic acid on the eradication of helicobacter pylori infection, serum inflammatory factors and total antioxidant capacity. Iranian journal of pharmaceutical research: IJPR. 2015;14(1):149–157. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous